

**Supplementary table 1 (S1). Tumour stage and grade by categories of fasting glucose in a sub-cohort excluding patients under anti-diabetic drugs and/or with fasting glucose  $\geq 126$  mg/dl (N:137).**

|                              |           | <sup>2</sup> FIGO        |                     |                            | Chi2<br>p-value |
|------------------------------|-----------|--------------------------|---------------------|----------------------------|-----------------|
|                              |           | I<br>N=22<br>n (%)       | II<br>N=13<br>n (%) | III - IV<br>N=102<br>n (%) |                 |
| <sup>1</sup> Fasting Glucose | $\leq 89$ | 11 (14.7)                | 3 (4.0)             | 61 (81.3)                  | 0.038           |
|                              | $> 89$    | 11 (17.7)                | 10 (16.1)           | 41 (66.1)                  |                 |
|                              |           |                          |                     |                            |                 |
|                              |           | <sup>3</sup> G           |                     |                            | Chi2<br>p-value |
|                              |           | G1 – G2<br>N=38<br>n (%) |                     | G3<br>N=99<br>n (%)        |                 |
| <sup>1</sup> Fasting Glucose | $\leq 89$ | 21 (28.0)                |                     | 54 (72.0)                  | 0.940           |
|                              | $> 89$    | 17 (27.4)                |                     | 45 (72.6)                  |                 |
|                              |           |                          |                     |                            |                 |

<sup>1</sup> mg/dl: milligrams/deciliter; <sup>2</sup>FIGO: Italian Federation Gynecology and Obstetrics; <sup>3</sup>Grade

**Supplementary table 2 (S2). Tumour stage by categories of <sup>1</sup>BMI (N:70).**

|            |               | <sup>2</sup> FIGO  |                     |                           | Chi2<br>p-value |
|------------|---------------|--------------------|---------------------|---------------------------|-----------------|
|            |               | I<br>N=13<br>n (%) | II<br>N=11<br>n (%) | III - IV<br>N=46<br>n (%) |                 |
| <b>BMI</b> | * $\leq 24.6$ | 5 (14.3)           | 6 (17.1)            | 24 (68.6)                 | 0.647           |
|            | $> 24.6$      | 8 (22.9)           | 5 (14.3)            | 22 (62.9)                 |                 |
|            |               |                    |                     |                           |                 |
| <b>BMI</b> | $< 25$        | 5 (13.9)           | 6 (16.7)            | 25 (69.4)                 | 0.584           |
|            | $\geq 25$     | 8 (23.5)           | 5 (14.7)            | 21 (61.8)                 |                 |
|            |               |                    |                     |                           |                 |
| <b>BMI</b> | $\leq 25$     | 5 (12.2)           | 8 (19.5)            | 28 (68.3)                 | 0.204           |
|            | $> 25$        | 8 (27.6)           | 3 (10.3)            | 18 (62.1)                 |                 |
|            |               |                    |                     |                           |                 |

<sup>1</sup> BMI: body mass index in kg/m<sup>2</sup>; <sup>2</sup>FIGO International Federation of Gynecology and Obstetrics;  
\*median value